Vascular endothelial growth factor (VEGF) and angiogenesis have been shown to promote ovarian cancer progression, and bevacizumab, a humanized monoclonal antibody targeting VEGF-A, inhibits tumor angiogenesis [4]. The gene discussed is VEGFA; the disease is ovarian cancer.